Oxford Biomedica Share News (OXB)

Dermatological treatments supplier Sinclair Pharma has agreed an extension of its partnership with Invida Group to include India. Invida has exclusivity for Sinclair's dermatology and wound care brands in 12 Asia Pacific countries. The two companies are preparing the initial launches in these markets. AXA has taken its stake in Sinclair to above 12%. Gene therapy treatments developer Oxford Biomedica says that the US FDA has approved its application for phase I/IIa clinical development of Stargen, a treatment for Stargardt disease. Oxford Biomedica's founder Dr Alan Kingsman is stepping down from the board and he is being replaced by Nick Rodgers. Goldman Sachs has cut its recommendation on Optos from buy to neutral. FTSE TechMARK - Risers Sinclair Pharma (SPH) 37.25p +7.19%Torotrak (TRK) 33.00p +6.45%Cable & Wireless Communications (CWC) 50.90p +5.36%Oxford Biomedica (OXB) 5.80p +4.50%Vodafone Group (VOD) 177.00p +4.15%Promethean World (PRW) 59.00p +3.06%Wolfson Microelectronics (WLF) 247.25p +3.02%KCOM Group (KCOM) 62.00p +2.90%Vectura Group (VEC) 64.25p +2.80%E2V Technologies (E2V) 104.00p +2.72%FTSE TechMARK - Fallers AEA Technology Group (AAT) 4.00p -7.51%Antisoma (ASM) 2.30p -4.17%Psion (PON) 90.75p -2.42%Emblaze Ltd. (BLZ) 40.25p -2.42%Optos (OPTS) 191.75p -1.92%RM (RM.) 150.25p -1.48%Oxford Instruments (OXIG) 630.00p -1.10%NCC Group (NCC) 580.00p -0.85%Phoenix IT Group (PNX) 210.00p -0.24%Consort Medical (CSRT) 528.00p -0.19%